Literature DB >> 16675238

Comparative hemodynamic effects of vasopressin and norepinephrine after milrinone-induced hypotension in off-pump coronary artery bypass surgical patients.

Yunseok Jeon1, Jung Hee Ryu, Young Jin Lim, Chong Sung Kim, Jae-Hyon Bahk, Seung Zhoo Yoon, Ju Youn Choi.   

Abstract

OBJECTIVE: Phosphodiesterase inhibitor is essential to the pharmacologic management of decompensated heart failure because it increases contractility and decreases afterload of right ventricle. It also improves hemodynamics and increases blood flow of the grafted internal mammary arteries and middle cerebral arteries during coronary artery bypass surgery. However, it induces vasodilation and necessitates the use of vasoconstrictors, such as norepinephrine. We hypothesized that vasopressin could recover hypotension induced by milrinone with less effect on pulmonary vascular resistance (PVR) compared to norepinephrine.
METHODS: Fifty patients, undergoing coronary artery bypass graft (CABG) surgery, were assigned randomly in a double-blind manner to receive either vasopressin or norepinephrine. After baseline hemodynamic measurements, a loading dose of milrinone 50 microg/kg was infused slowly for 20 min followed by continuous infusion of 0.5 microg/(kg min). Immediately after the loading dose of milrinone, hemodynamic variables were measured, and vasopressin (VP group) or norepinephrine (NE groups) was infused. After being titrated until the mean arterial pressure was increased by 20%, hemodynamic variables were measured again.
RESULTS: Milrinone infusion reduced both systemic vascular resistance (SVR, 1218+/-299 dynes/cm5 vs 838+/-209 dynes/cm5, 1345+/-299 dynes/cm5 vs 1011+/-195 dynes/cm5) and PVR (95+/-34 dynes/cm5 vs 72+/-30 dynes/cm5, 119+/-85 dynes/cm5 vs 87+/-33 dynes/cm5) in the VP and NE groups, respectively. Vasopressin and norepinephrine infusion increased both SVR (838+/-209 dynes/cm5 vs 1100+/-244 dynes/cm5, 1011+/-195 dynes/cm5 vs 1446+/-681 dynes/cm5, respectively) and PVR (72+/-30 dynes/cm5 vs 84+/-18 dynes/cm5, 87+/-33 dynes/cm5 vs 139+/-97 dynes/cm5, respectively). The PRV/SVR ratio was decreased after vasopressin infusion (0.10+/-0.03 vs 0.08+/-0.03), while no changes were found after norepinephrine infusion (0.09+/-0.02 vs 0.09+/-0.02).
CONCLUSIONS: In the patients undergoing CABG surgery, both norepinephrine and low dose vasopressin were effective in restoring milrinone-induced decrease of SVR. However, only low-dose vasopressin decreased the PVR/SVR ratio that was increased by milrinone. Considering the importance of maintaining systemic perfusion pressure as well as reducing right heart afterload, milrinone-vasopressin may provide better hemodynamics than milrinone-norephinephrine during the management of right heart failure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16675238     DOI: 10.1016/j.ejcts.2006.02.032

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  A retrospective comparison of inhaled milrinone and iloprost in post-bypass pulmonary hypertension.

Authors:  Kassiani Theodoraki; Apostolos Thanopoulos; Panagiota Rellia; Evangelos Leontiadis; Dimitrios Zarkalis; Konstantinos Perreas; Theophani Antoniou
Journal:  Heart Vessels       Date:  2017-07-17       Impact factor: 2.037

Review 2.  Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review.

Authors:  Laura C Price; Stephen J Wort; Simon J Finney; Philip S Marino; Stephen J Brett
Journal:  Crit Care       Date:  2010-09-21       Impact factor: 9.097

3.  Effect of arginine vasopressin on systemic and pulmonary arterial pressure in a patient with pulmonary hypertension secondary to pulmonary emphysema: a case report.

Authors:  Toshiyuki Mizota; Kohei Fujiwara; Miho Hamada; Shino Matsukawa; Hajime Segawa
Journal:  JA Clin Rep       Date:  2017-01-04

4.  Terlipressin versus norepinephrine to prevent milrinone-induced systemic vascular hypotension in cardiac surgery patient with pulmonary hypertension.

Authors:  Mai Mohsen Abdelazziz; Hadil Magdi Abdelhamid
Journal:  Ann Card Anaesth       Date:  2019 Apr-Jun

Review 5.  Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure.

Authors:  Angel Coz Yataco; Melina Aguinaga Meza; Ketan P Buch; Margaret A Disselkamp
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 6.  Arterial pulmonary hypertension in noncardiac intensive care unit.

Authors:  Mykola V Tsapenko; Arseniy V Tsapenko; Thomas Bo Comfere; Girish K Mour; Sunil V Mankad; Ognjen Gajic
Journal:  Vasc Health Risk Manag       Date:  2008
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.